FDA approves new treatment for paediatric patients with any strain of Hepatitis C

This article was originally published here

Epclusa in combination with ribavirin is indicated for the treatment of pediatric patients 6 years and older or weighing at least 37 pounds with severe cirrhosis. The FDA

The post FDA approves new treatment for paediatric patients with any strain of Hepatitis C appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply